Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that specializes in computational target discovery [1][3] - The company will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025 [1][2] Company Overview - Compugen utilizes its predictive computational discovery platform, Unigen™, to identify new drug targets and biological pathways for cancer immunotherapies [3] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3] - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3] - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]